---
title: "The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What Investors Need to Know"
description: "Novo Nordisk's stock is climbing following FDA approval of Wegovy for treating metabolic dysfunction-associated steatohepatitis (MASH). This new indication could add over $1 billion in sales, tapping "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254002090.md"
published_at: "2025-08-21T12:49:47.000Z"
---

# The FDA Just Approved a New Use for Wegovy, and Novo Nordisk Stock is Climbing. Here's What Investors Need to Know

> Novo Nordisk's stock is climbing following FDA approval of Wegovy for treating metabolic dysfunction-associated steatohepatitis (MASH). This new indication could add over $1 billion in sales, tapping into a significant market with few approved therapies. The company also partners with GoodRx to reduce Ozempic costs. Despite recent challenges, Novo Nordisk's financials remain strong, with a 16% sales growth in the first half of the year. Analysts predict future blockbusters in its pipeline, making the stock potentially undervalued at 13.5 times forward earnings, compared to the healthcare industry's average of 16.5.

The past 12 months haven't been great for **Novo Nordisk** (NVO -0.89%). Its shares peaked last year and have been in a downward spiral due to unimpressive financial results, clinical setbacks, and mounting competition in its core areas of expertise.

However, Novo Nordisk is looking to bounce back. Recent regulatory progress could be a positive step in that direction. Here's what investors need to know.

## Another important approval

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a household name, famous for helping people manage their weight, but this new indication could be a significant development. Here's why.

MASH is a disease characterized by the accumulation of fat in the liver, leading to inflammation. According to some estimates, 22 million adults in the U.S. have MASH, although fewer, about 9 million, have clinically meaningful liver disease.

That's not an insignificant number, and one might think that, given this large addressable market, there are many approved therapies for MASH. But that's not the case. Developing effective treatments has proven to be surprisingly challenging. Last year, the FDA approved the first therapy specifically for MASH.

Image source: Getty Images.

Now, Wegovy has become the first GLP-1 medicine to earn that indication. Although there are other treatments in development, Wegovy could carve out a decent market for itself in MASH, especially since it posted phase 3 results comparable to those of its only competitor on the market (for now): Rezdiffra, marketed by **Madrigal Pharmaceuticals**. Novo Nordisk is a significantly larger company with more funds, a larger marketing budget, and a larger sales team than its smaller peer.

What will be the demand for Wegovy in MASH be? We can gather some clues from Rezdiffra's launch, which is going extremely well. About a year after it hit the market, Rezdiffra generated $212.8 million in revenue in the second quarter -- that's impressive and points to a massive demand for the medicine. Yet, Madrigal has barely scratched the surface of the addressable market. As of June 30, it had treated just over 23,000 patients.

Wegovy's launch in MASH should be even smoother since it isn't starting from scratch -- it's already been on the market for several years. In my view, this new indication could add over $1 billion in sales to Wegovy's total within the next few years, especially because it's also being considered for approval for MASH in Japan and the European Union.

It's also worth pointing out another development that helped jolt Novo Nordisk's stock price. The company is partnering with GoodRx to offer Ozempic at a reduced cost for patients who pay out of pocket. This move should help it deal with some companies that sell compounded versions of Ozempic for less.

## Is Novo Nordisk's stock a buy?

Wegovy could earn yet another important label expansion by next year, although in a different version. Earlier this year, Novo Nordisk requested approval for an oral formulation of the medicine for weight loss. That could also move the needle for the pharmaceutical giant. An oral version would be faster and cheaper to produce, easier to transport, and thus more cost-effective to manufacture at scale. The previous shortages Wegovy dealt with would be far less likely to occur with an oral formulation.

Notably, it would mark yet another breakthrough for Novo Nordisk. There is currently no oral GLP-1 medication approved for weight loss -- the drugmaker's own Rybelsus, an oral GLP-1 product, is indicated only for diabetes.

Meanwhile, Novo Nordisk's financial results remain strong. In the first half of the year, net sales grew by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit of 55.5 billion DKK ($8.7 billion) rose 22% compared to the year-ago period.

Furthermore, Novo Nordisk has an attractive pipeline. CagriSema, a next-generation GLP-1 therapy whose phase 3 results were strong (if not as strong as the market had hoped), appears poised to become a blockbuster. Some analysts predict that it will generate $15.2 billion in revenue by 2030.

Elsewhere, Novo Nordisk's amycretin, another investigational weight loss therapy, recently started phase 3 studies in both oral and subcutaneous formulations. Despite recent clinical setbacks, Novo Nordisk's pipeline should earn some significant wins in the next few years, particularly since the company has been strengthening it through licensing deals.

Lastly, Novo Nordisk stock looks reasonably valued. The company is trading at 13.5 times forward earnings, compared to an average price-to-earnings ratio of 16.5 for the healthcare industry. At current levels, the stock could deliver superior returns to investors who initiate positions today.

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 靈北公司發佈了針對董事會和管理層的新薪酬政策 | H. Lundbeck A/S 已經推出了一項新的董事會和管理層薪酬政策，生效日期為 2026 年 3 月 18 日。該政策允許在特殊情況下進行偏離，例如一次性獎金或特別激勵，這些將在不再必要時暫停。該政策將至少每四年進行一次審查，並可在公 | [Link](https://longbridge.com/en/news/276108951.md) |
| 諾和諾德公司將在其愛爾蘭工廠生產 Wegovy | 諾和諾德公司將在愛爾蘭工廠生產 Wegovy | [Link](https://longbridge.com/en/news/275789396.md) |
| 關於諾和諾德公司電視廣告的文章糾正於 2 月 9 日 | 安吉拉·穆尼奧斯是諾和諾德公司的監管事務總監。美國食品藥品監督管理局（FDA）在 2 月 9 日下午 3:32 發佈的消息中錯誤地稱她為首席執行官，標題為 “諾和諾德口服 Wegovy 的電視廣告存在誤導性聲明”。（完）道瓊斯通訊社 02- | [Link](https://longbridge.com/en/news/275669553.md) |
| GLP-1 類藥物可能會導致患者出現壞血病 | GLP-1 減肥藥物，包括 Ozempic 和 Wegovy，與壞血病病例相關，這是一種由維生素 C 缺乏引起的罕見疾病。紐卡斯爾健康科學學院的 Clare Collins 的研究強調了使用這些藥物的患者可能面臨的營養不良風險。壞血病的症狀 | [Link](https://longbridge.com/en/news/275772745.md) |
| 諾和諾德公司計劃開始銷售其減肥重磅藥物 Wegovy 的瓶裝版本 - 彭博社 | 諾和諾德公司計劃開始以小瓶形式銷售其減肥暢銷藥 Wegovy - 彭博新聞 | [Link](https://longbridge.com/en/news/275654518.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.